Preclinical Imaging Market
Report ID: SQMIG35D2366
Report ID: SQMIG35D2366
sales@skyquestt.com
USA +1 351-333-4748
Report ID:
SQMIG35D2366 |
Region:
Global |
Published Date: January, 2026
Pages:
189
|Tables:
91
|Figures:
68
Global Preclinical Imaging Market size was valued at USD 3.77 Billion in 2024 and is poised to grow from USD 3.95 Billion in 2025 to USD 5.75 Billion by 2033, growing at a CAGR of 4.8% during the forecast period (2026–2033).
The preclinical imaging industry is experiencing significant growth, primarily influenced by an increase in demand for advanced research instruments in drug discovery, molecular biology, and translational medicine. Preclinical imaging is vital in evaluating the efficacy and safety of potential new drug candidates, understanding disease progression, and providing support for the development of personalized therapies.
Growth in the industry is supported by increases in the prevalence of chronic diseases, cancer, and neurological diseases that require precise and non-invasive imaging techniques to study disease mechanisms in animals models. Recent technological advances, such as the availability of high-resolution MRI, PET, CT, Optical imaging, multimodal imaging systems, etc., are improving the researchers’ ability to visualize biological processes at cellular and subcellular and molecular levels in real-time in vivo.
The use of AI and machine learning in imaging analysis is enabling the development of more accurate imaging and interpretation and increased throughput of data analysis. The industry is also benefitting from increased funding and investment into pharmaceutical and biotechnology research and development, an increased collaboration between academic institutions, CROs, and imaging solution providers who acknowledge the need for reproducible, scalable and efficient imaging solutions for preclinical studies. The continued increases in demand for more efficient, reproducible, and scalable imaging solutions for pre-clinical studies also reflects the predicted growth and innovative preclinical imaging market here.
How is AI Enhancing Data Analysis in Preclinical Imaging?
In 2024, the preclinical imaging market was transformed through advancement in Artificial Intelligence (AI) that improved the accuracy, efficiency, and scalability of imaging modalities in the search for biologic mechanisms in drug applications and disease research. The advancement of AI algorithms made it possible to analyze large sets of complex imaging data to yield biologically convincing, detailed insights with imaging modalities such as MRI, PET, CT, and optical imaging. With the ability to automatically segment tissues, quantify tumor heterogeneity, and identify subtle biomarkers, AI-generated and analyzed data can significantly speed up therapeutic evaluations and, in turn, provide a better model for human disease in animal models. AI has also helped pioneer generative models to synthesize imaging data and to decrease the need for animal studies so that each can be reproducible in terms of experimental design. For example, Pose2Xray generates synthetic x-rays from photographic images of mice. DosimetrEYE takes a 2D SPECT/CT scan and estimates 3D radiation dose maps based on the original images. These tools gather data to improve efficiency, reduce costs, and encourage high-throughput data.
Market snapshot - 2026-2033
Global Market Size
USD 2.8 Billion
Largest Segment
Disease Research
Fastest Growth
Drug Discovery & Development
Growth Rate
4.30% CAGR
To get more insights on this market click here to Request a Free Sample Report
Global Preclinical Imaging Market is segmented by Component, Modality, Application and region. Based on Component, the market is segmented into Hardware Systems and Software & Services. Based on Modality, the market is segmented into Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), Computed Tomography (CT), Optical Imaging, Ultrasound Imaging, Single Photon Emission Computed Tomography (SPECT) and Multimodal Imaging. Based on Application, the market is segmented into Drug Discovery & Development, Disease Research, Translational Medicine and Toxicology Studies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Magnetic resonance imaging (MRI) segment dominates the market because of its high-resolution, non-invasive imaging ability, and flexibility in studying, anatomically, functionally, and molecularly, disease processes. MRI allows researchers to assess the trajectory and outcome of disease, assess therapeutic impact, and non-invasively delineate soft tissue components, which makes it the preferred imaging modality for studies in oncology, neurology, and cardiovascular disease. The availability of longitudinal imaging for the same subject, without exposing them to radiation, also contributes to the favorable adoption of MRI in preclinical research.
Optical imaging, which includes both fluorescence and bioluminescence imaging, is the fastest growing modality segment. This approach relies on its cost-effective and real-time imaging abilities of sensitive cellular- and molecular-level imaging processing. Optical imaging is useful for high-throughput drug development studies, as well as to study gene expression, to monitor tumor development, and stage therapy response in small animal models.
As per preclinical imaging market analysis, the drug discovery & development segment leads the industry, primarily due to the rising demand for accurately and efficiently assessing new drug candidates during preclinical investigations. Imaging modalities are widely used by biotechnology and pharmaceutical companies to track therapeutic efficacy, evaluate pharmacokinetics, and assess toxicity in animals. Preclinical imaging allows scientists to visualize disease progression, assess treatment responses, and identify optimized lead compounds before the advent of clinical trials. As a whole, preclinical imaging is a necessary and strong component of drug development pipelines.
As per preclinical imaging market outlook, the disease research segment is the fastest-growing segment and grows due to the ever-increasing presence of chronic, life-threatening diseases that spur investment in research for targeted therapies. Optical imaging, MRI, PET, and multimodal solutions are widely utilized in disease research to observe tumor progression, changes of neurodegeneration, and cardiovascular abnormalities in models of human disease. AI and high-throughput imaging innovations and the desire to analyze data quickly and analyze more precise models of human diseases in preclinical studies contribute to growth.
To get detailed segments analysis, Request a Free Sample Report
As per regional outlook, the North America region is the largest market in the world to largely varied research funding/image modalities, highly developed health care structures, and the highest collection of biopharmaceutical and biotechnology industries concentrated in the world. North America also holds a general preclinical imaging research application history with routine use of preclinical imaging knowledge anywhere with a high concentration of academic institutions, researchers, chips, and a long-standing culture of research, which encourages new technologies around imaging modalities for drug discovery and disease investigation.
The preclinical imaging market trends in the U.S. has the largest preclinical imaging research market share due to investments/development in preclinical imaging image modalities, biopharmaceutical pipelines, academic partnerships, and industrial partnerships. National Institutes of Health (NIH) is one of the most active and the leading provider offering a variety of grants, which leads to the largest amount of regions activity with the most advanced imaging research, particularly in imaging research in oncological and neurological disease.
As per regional forecast, the preclinical imaging market in Canada is steadily developing. There is more government research and grants to build activities around biopharma research, and the use of preclinical imaging activity, particularly in translation medicine, is rising. As there are advances with translational animal research use with ethical concerns, new education and firm partnerships are developing quicker because to the support of animal use, ethics, and developing imaging techniques that limit animal use by using longitudinal preclinical imaging studies.
The Asia-Pacific market is developing as the highest-growth area in the preclinical imaging market, backed by growing investments in healthcare, pharmaceutical research, and the need for advanced tools for drug discovery. The countries in Asia-Pacific are dedicated to improving modern infrastructure for research and creating public-private partnerships in preclinical research.
Japan is an important player in the region, with advanced technical capabilities, a strong presence of the pharmaceutical industry, and government backing in research in the life sciences. MRI and PET modalities are frequently used in oncology and neurological studies.
South Korea is increasing its foothold in the preclinical imaging market, with more investment in translational research, innovative pipelines of biopharmaceuticals, and academic-industry partnerships. Likewise, AI has been incorporated into imaging.
As per industry analysis, Europe is an important and developed market, with established pharmaceutical companies, research institutes, and funding for life science innovation. Europe is taking the lead in the integration of imaging modalities, machine learning or AI for data analysis, and applications in translational medicine. Furthermore, the market is also accelerated by collaborative research across countries in Europe.
Germany is the leader in the European market, with a strong pharmaceutical R&D community, leading the way in adopting imaging technologies and developing a combination with the biotech industry. Germany is also actively investing in oncology and neurology research, which accounts for a high demand for the MRI and PET types of imaging.
The UK continues to benefit from having a strong academic research culture, government-backed innovation, and much of the life science development is clustered in the UK. The growing number of AI-driven imaging analytics also strengthens the market.
Italy is an emerging market in Europe, as the utilization of preclinical imaging in research in disease research and drug discovery is growing. The market is being driven by efforts among universities, hospitals, and biotech companies working together.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Increasing Demand for Advanced Drug Discovery and Disease Research
Technological Advances in Imaging Modalities
Costs of Preclinical Imaging Equipment
Regulatory & Ethical Challenges
Request Free Customization of this report to help us to meet your business objectives.
In 2024, the preclinical imaging industry is characterized by a combination of established global incumbents and new, innovative startups, all seeking to provide advanced imaging solutions to support drug discovery and disease research. For example, key players such as Bruker Corporation, PerkinElmer, Siemens Healthineers, Canon Medical Systems, and Miltenyi Biotec continue to lead the market due to their wide-ranging product portfolios, advances in technology, and global presence. These companies are investing significantly in high-resolution and multimodal imaging systems, AI, and software analytics in order to sustain competitiveness.
As per market strategies, PerkinElmer enhanced its preclinical imaging portfolio with AI-enabled analytics, and Bruker launched a next generation small-animal MRI system that offers improved resolution and throughput.
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
As per SkyQuest analysis, the preclinical imaging sector is undergoing rapid expansion fueled by the growing need for advanced imaging modalities for drug discovery, disease investigation, and translational medicine. Initial growth arises from the increased prevalence of chronic diseases, cancer, and neurological disorders that generate an increased need for accurate and non-invasive imaging to study mechanisms of disease in animal models. Improvements in high-resolution MRI, PET, CT, optical imaging, multimodal systems, and other modalities, in tandem with technology trajectories, are improving the ability to visualize biological processes at cellular and molecular levels. The applications of artificial intelligence and machine learning are transforming the market to allow automated image analysis, predictive modeling, and reproducibility, while also reducing reliance on extensive use of animal models. Pharmaceutical companies, biotechnology companies or firms, academic institutions, and other key players are investing to drive market growth and collaborate or innovate, which contributes to the overall expansion of the market. The overall view of the preclinical imaging market is that it is presently growing rapidly and providing more efficient, more accurate, and scalable models to support faster drug development and enhanced data-driven, ethical research paradigms.
| Report Metric | Details |
|---|---|
| Market size value in 2024 | USD 3.77 Billion |
| Market size value in 2033 | USD 5.75 Billion |
| Growth Rate | 4.8% |
| Base year | 2024 |
| Forecast period | 2026-2033 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Table Of Content
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
Methodology
For the Preclinical Imaging Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Preclinical Imaging Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Preclinical Imaging Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Preclinical Imaging Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
REQUEST FOR SAMPLE
REQUEST FREE CUSTOMIZATION
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Feedback From Our Clients
USA (+1) 351-333-4748
